DSM Forecasts Challenging 2014 as Currencies Hurt Profit

Royal DSM NV (DSM), the world’s largest vitamin maker, said it’s taking a “prudent approach” to business in 2014 because of doubts over the economy after exchange-rate shifts held back earnings last year.

“DSM assumes a continued challenging macro-economic environment, with low growth in Europe, modest growth in the U.S., and a slowdown in the high growth economies,” Chief Executive Officer Feike Sijbesma said today in a statement.

Full-year earnings before interest, taxes, depreciation and amortization jumped 20 percent to 1.31 billion euros ($1.78 billion) from 1.11 billion euros a year earlier, Heerlen, Netherlands-based DSM. The company had forecast earnings to be “slightly below” 1.35 billion euros. Currency moves in the fourth quarter held back revenue by 2 percent to 4 percent, and the effect this year may total 70 million euros, DSM said.

To contact the reporter on this story: Fred Pals in Amsterdam at fpals@bloomberg.net

To contact the editor responsible for this story: Simon Thiel at sthiel1@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.